Advances in clinical NK cell studies: Donor selection, manufacturing and quality control
Ulrike Koehl(Leipzig University), Evren Alici(Karolinska Institutet), Jeffrey S. Miller(Science Museum of Minnesota), Christian P. Kalberer(Amgen (United States)), Wing Leung(KK Women's and Children's Hospital), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Antonio Curti(Istituto di Ematologia di Bologna), Sarah Cooley(Palmetto Hematology Oncology), L. Uharek(Charité - Universitätsmedizin Berlin), Mark W. Lowdell(Royal Free London NHS Foundation Trust), Hans Klingemann(Tufts Medical Center), Dean A. Lee(Nationwide Children's Hospital)
Cited by 111
Related Papers
NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
|Journal of Clinical Oncology|2010|648
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
|The Lancet Oncology|2010|586
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis.
|Journal of Clinical Investigation|1989|460
Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2003|453